Evotec AG has acquired Bionamics GmbH, an asset management company based in Germany that focuses on translating academic innovations into assets for the pharma and biopharma industry. Bionamics brings a portfolio of fully funded projects including focus areas in neurodegeneration and CNS. Evotec has acquired all shares of Bionamics for cash and future milestone payments. Financial details were not disclosed.
Dr. Timm Jessen has been appointed executive vice president of business development for the company’s “EVT Innovate" strategy and will work to enhance translation capabilities.
Dr. Werner Lanthaler, chief executive officer of Evotec, said, "With the acquisition of Bionamics we accelerate our EVT Innovate strategy and enlarge our reach towards outstanding innovations. We welcome the openness of Bionamics to join the discovery infrastructure of Evotec. We are also very happy to welcome Dr. Timm Jessen back at Evotec. In his new management role, Dr. Jessen will be responsible for the commercialization of "EVT Innovate" projects."
Dr. Timm Jessen, managing director of Bionamics GmbH, said, "We highly value Evotec's strategic appreciation of our work and its success as demonstrated e.g. in managing the NEU² program, a consortium of academic, biotech and Pharma partners focusing on novel products to treat Multiple Sclerosis and other neurodegenerative diseases. The combination of our management skills with Evotec's strong operational capabilities offers a unique constellation for researchers and entrepreneurs around the globe to accelerate their innovation together with us. I very much look forward to expand this concept further within the Evotec Group."